Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NBIX's Cash to Debt is ranked higher than
97% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. NBIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NBIX' s 10-Year Cash to Debt Range
Min: 1.72  Med: 37.81 Max: No Debt
Current: No Debt
Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
96% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. NBIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NBIX' s 10-Year Interest Coverage Range
Min: 2.5  Med: 10000.00 Max: 9999.99
Current: No Debt
2.5
9999.99
F-Score: 5
Z-Score: 56.10
M-Score: 7.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -328.47
NBIX's Operating margin (%) is ranked lower than
93% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. NBIX: -328.47 )
Ranked among companies with meaningful Operating margin (%) only.
NBIX' s 10-Year Operating margin (%) Range
Min: -17340.03  Med: -91.95 Max: 43.82
Current: -328.47
-17340.03
43.82
Net-margin (%) -306.02
NBIX's Net-margin (%) is ranked lower than
93% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. NBIX: -306.02 )
Ranked among companies with meaningful Net-margin (%) only.
NBIX' s 10-Year Net-margin (%) Range
Min: -16936.19  Med: -94.75 Max: 48.53
Current: -306.02
-16936.19
48.53
ROE (%) -18.66
NBIX's ROE (%) is ranked lower than
81% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. NBIX: -18.66 )
Ranked among companies with meaningful ROE (%) only.
NBIX' s 10-Year ROE (%) Range
Min: -250.63  Med: -23.98 Max: 94.61
Current: -18.66
-250.63
94.61
ROA (%) -16.72
NBIX's ROA (%) is ranked lower than
82% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. NBIX: -16.72 )
Ranked among companies with meaningful ROA (%) only.
NBIX' s 10-Year ROA (%) Range
Min: -62.22  Med: -18.62 Max: 26.57
Current: -16.72
-62.22
26.57
ROC (Joel Greenblatt) (%) -1010.13
NBIX's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. NBIX: -1010.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NBIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3011.27  Med: -152.59 Max: 2175.88
Current: -1010.13
-3011.27
2175.88
Revenue Growth (3Y)(%) -100.00
NBIX's Revenue Growth (3Y)(%) is ranked lower than
98% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NBIX: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NBIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: -10.80 Max: 175.9
Current: -100
-100
175.9
» NBIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NBIX Guru Trades in Q2 2014

Pioneer Investments 511,617 sh (+17.74%)
» More
Q3 2014

NBIX Guru Trades in Q3 2014

Pioneer Investments 503,938 sh (unchged)
» More
Q4 2014

NBIX Guru Trades in Q4 2014

Pioneer Investments 238,621 sh (-52.65%)
» More
Q1 2015

NBIX Guru Trades in Q1 2015

Steven Cohen 233,200 sh (New)
Paul Tudor Jones 6,635 sh (New)
RS Investment Management 596,880 sh (New)
Pioneer Investments 193,871 sh (-18.75%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.20
NBIX's P/B is ranked lower than
84% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. NBIX: 9.20 )
Ranked among companies with meaningful P/B only.
NBIX' s 10-Year P/B Range
Min: 0.9  Med: 5.04 Max: 108
Current: 9.2
0.9
108
P/S 201.58
NBIX's P/S is ranked lower than
98% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. NBIX: 201.58 )
Ranked among companies with meaningful P/S only.
NBIX' s 10-Year P/S Range
Min: 3.15  Med: 26.07 Max: 3940
Current: 201.58
3.15
3940
EV-to-EBIT -57.85
NBIX's EV-to-EBIT is ranked lower than
180% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. NBIX: -57.85 )
Ranked among companies with meaningful EV-to-EBIT only.
NBIX' s 10-Year EV-to-EBIT Range
Min: -165.7  Med: -3.50 Max: 426.3
Current: -57.85
-165.7
426.3
Current Ratio 22.19
NBIX's Current Ratio is ranked higher than
97% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. NBIX: 22.19 )
Ranked among companies with meaningful Current Ratio only.
NBIX' s 10-Year Current Ratio Range
Min: 1.63  Med: 9.38 Max: 26.66
Current: 22.19
1.63
26.66
Quick Ratio 22.19
NBIX's Quick Ratio is ranked higher than
97% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. NBIX: 22.19 )
Ranked among companies with meaningful Quick Ratio only.
NBIX' s 10-Year Quick Ratio Range
Min: 1.63  Med: 9.38 Max: 26.66
Current: 22.19
1.63
26.66
Days Sales Outstanding 554.45
NBIX's Days Sales Outstanding is ranked lower than
99% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. NBIX: 554.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
NBIX' s 10-Year Days Sales Outstanding Range
Min: 2.53  Med: 32.27 Max: 149.47
Current: 554.45
2.53
149.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.62
NBIX's Price/Net Cash is ranked lower than
53% of the 181 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.71 vs. NBIX: 12.62 )
Ranked among companies with meaningful Price/Net Cash only.
NBIX' s 10-Year Price/Net Cash Range
Min: 2.62  Med: 8.53 Max: 254.67
Current: 12.62
2.62
254.67
Price/Net Current Asset Value 12.44
NBIX's Price/Net Current Asset Value is ranked lower than
65% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.66 vs. NBIX: 12.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NBIX' s 10-Year Price/Net Current Asset Value Range
Min: 1.79  Med: 6.47 Max: 280
Current: 12.44
1.79
280
Price/Tangible Book 9.20
NBIX's Price/Tangible Book is ranked lower than
77% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. NBIX: 9.20 )
Ranked among companies with meaningful Price/Tangible Book only.
NBIX' s 10-Year Price/Tangible Book Range
Min: 1.11  Med: 4.50 Max: 101.67
Current: 9.2
1.11
101.67
Price/Projected FCF 16.43
NBIX's Price/Projected FCF is ranked lower than
92% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. NBIX: 16.43 )
Ranked among companies with meaningful Price/Projected FCF only.
NBIX' s 10-Year Price/Projected FCF Range
Min: 9.63  Med: 31.88 Max: 93.08
Current: 16.43
9.63
93.08
Price/Median PS Value 7.69
NBIX's Price/Median PS Value is ranked lower than
99% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. NBIX: 7.69 )
Ranked among companies with meaningful Price/Median PS Value only.
NBIX' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 0.75 Max: 60.27
Current: 7.69
0.14
60.27
Earnings Yield (Greenblatt) (%) -1.69
NBIX's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. NBIX: -1.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NBIX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.69  Med: 8.60 Max: 3683.9
Current: -1.69
-1.69
3683.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NB3.Germany,
Neurocrine Biosciences Inc, a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. Its product candidates address pharmaceutical markets internationally, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company's two late-stage clinical programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II clinical studies of uterine fibroids that is partnered with AbbVie, and a wholly owned VMAT2 inhibitor for the treatment of movement disorders that is currently in Phase II development. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

More From Other Websites
NBIX: Three More Data Readouts Coming in the Second Half of 2015 - Analyst Blog Jul 30 2015
NBIX: Three More Data Readouts Coming in the Second Half of 2015… Jul 30 2015
Edited Transcript of NBIX earnings conference call or presentation 29-Jul-15 9:00pm GMT Jul 29 2015
Neurocrine reports 2Q loss Jul 29 2015
Neurocrine reports 2Q loss Jul 29 2015
Neurocrine Biosciences Reports Second Quarter 2015 Results Jul 29 2015
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2015
Neurocrine Biosciences Reports Second Quarter 2015 Results Jul 29 2015
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results Jul 22 2015
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results Jul 22 2015
Amicus Therapeutics, Inc. (FOLD), Neurocrine Biosciences, Inc. (NBIX), and Retrophin Inc (RTRX)... Jun 25 2015
More Than 60% Returns For These Two Hedgies’ Favorite Health Care Picks Jun 24 2015
Aeropostale, SouFun, Cyberark Led Monday's After-Hours Movers Jun 09 2015
Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia Jun 08 2015
Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia Jun 08 2015
Neurocrine Biosciences, Inc. Announces Appointment of Eric Benevich as Chief Commercial Officer Jun 02 2015
Neurocrine Biosciences, Inc. Announces Appointment of Eric Benevich as Chief Commercial Officer Jun 02 2015
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 01 2015
Neurocrine Biosciences to Present at the Jefferies 2015 Healthcare Conference May 27 2015
Neurocrine Biosciences to Present at the Jefferies 2015 Healthcare Conference May 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK